The stock of Verastem Inc. (NASDAQ:VSTM) last traded at $0.34, up 4.33% from the previous session.
Data from the available sources indicates that Verastem Inc. (NASDAQ:VSTM) is covered by 6 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.50 and a low of $3.00, we find $4.50. Given the previous closing price of $0.33, this indicates a potential upside of 1263.64 percent. VSTM stock price is now -12.06% away from the 50-day moving average and -65.50% away from the 200-day moving average. The market capitalization of the company currently stands at $77.72M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $4.25 as their price target over the next twelve months.
, while ‘RBC Capital Mkts’ rates the stock as ‘Outperform’.
In other news, Paterson Dan, President and COO sold 2,954 shares of the company’s stock on Dec 19. The stock was sold for $1,093 at an average price of $0.37. Upon completion of the transaction, the President and COO now directly owns 463,828 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19, Director Gagnon Robert E. sold 1,429 shares of the business’s stock. A total of $529 was realized by selling the stock at an average price of $0.37. This leaves the insider owning 574,717 shares of the company worth $0.2 million. Insiders disposed of 144,635 shares of company stock worth roughly $49175.9 over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VSTM stock. A new stake in Verastem Inc. shares was purchased by ORBIMED ADVISORS LLC during the first quarter worth $5,917,000. JACOBS LEVY EQUITY MANAGEMENT, INC invested $130,000 in shares of VSTM during the first quarter. In the first quarter, BRIDGEWAY CAPITAL MANAGEMENT, LLC acquired a new stake in Verastem Inc. valued at approximately $122,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in VSTM for approximately $42,000. GSA CAPITAL PARTNERS LLP purchased a new stake in VSTM valued at around $22,000 in the second quarter. In total, there are 159 active investors with 62.10% ownership of the company’s stock.
With an opening price of $0.3319 on Wednesday morning, Verastem Inc. (NASDAQ: VSTM) set off the trading day. During the past 12 months, Verastem Inc. has had a low of $0.29 and a high of $2.27. As of last week, the company has a debt-to-equity ratio of 0.39, a current ratio of 5.00, and a quick ratio of 5.00. The fifty day moving average price for VSTM is $0.3922 and a two-hundred day moving average price translates $0.9981 for the stock.
The latest earnings results from Verastem Inc. (NASDAQ: VSTM) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.12, missing analysts’ expectations of -$0.11 by -0.01. This compares to -$0.13 EPS in the same period last year.
Verastem Inc.(VSTM) Company Profile
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen’s KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
